Findings show survival benefits for both risk-reducing mastectomy and salpingo-oophorectomy<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Dec. 16, 2024 (HealthDay News) — Risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO) are both associated with significant improvements in outcomes among young BRCA<\/em> carriers with breast cancer, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio.<\/p>\n Matteo Lambertini, M.D., Ph.D., from the University of Genova-IRCCS Policlinico San Martino Hospital in Genoa, Italy, and colleagues investigated the association between RRM and\/or RRSO and survival outcomes among young BRCA<\/em> carriers with breast cancer. The analysis included 5,292 women with germline BRCA1<\/em> and\/or BRCA2<\/em> pathogenic variants diagnosed with stage I to III invasive breast cancer at 40 years of age or younger (2000 through 2020).<\/p>\n The researchers found that during a median follow-up of 8.2 years, RRM and RRSO were both associated with improved outcomes. Patients who underwent RRM had a 35 percent lower risk for death and a 42 percent lower risk for breast cancer recurrence or second primary malignancy, while those who underwent RRSO had a 42 percent lower risk for death and a 32 percent lower risk for breast cancer recurrence or second primary malignancy. For RRM, improved outcomes were seen whether or not the germline BRCA<\/em> mutation was present in the BRCA1<\/em> or BRCA2<\/em> gene; however, for RRSO, overall survival varied, with a greater survival benefit seen for patients with germline mutations in BRCA1<\/em> than in BRCA2<\/em> (56 and 15 percent lower risk for death, respectively). For patients undergoing RRSO, the greatest survival benefits were seen for triple-negative and hormone receptor-positive breast cancers (56 and 20 percent lower risk for death, respectively). Among patients who underwent both surgeries and those who had only one surgery, overall survival was similar.<\/p>\n “These findings are critical for improving the counseling of young BRCA<\/em> carriers with breast cancer on cancer risk management strategies,” the authors write.<\/p>\n One author disclosed ties to the pharmaceutical industry.<\/p>\n